Advertisement

Molecular and Cellular Biochemistry

, Volume 378, Issue 1–2, pp 1–7 | Cite as

The novel estrogen receptor GPER regulates the migration and invasion of ovarian cancer cells

  • Yan Yan
  • Huidi Liu
  • Haixia Wen
  • Xueli Jiang
  • Xuefeng Cao
  • Guangmei Zhang
  • Guoyi Liu
Article

Abstract

G protein-coupled estrogen receptor (GPER) was identified as a new member of the estrogen receptor family in recent years. It has become apparent that GPER mediates the non-genomic signaling of 17β-estradiol (E2) in a variety of estrogen-related cancers. Our previous study has found that GPER was overexpressed in human epithelial ovarian cancer and was positively correlated with the expression of matrix metalloproteinase 9 (MMP-9), which suggested GPER might promote the metastasis of ovarian cancer. However, the mechanisms underlying GPER-dependent metastasis of ovarian cancer are still not clear. In the present study, estrogen receptor α (ERα)-negative/GPER-positive OVCAR5 ovarian cancer cell line was used to investigate the role of GPER in the migration and invasion of ovarian cancer. Wound healing assay and transwell matrigel invasion assay were performed to determine the potentials of cell migration and invasion, respectively. The production and activity of MMP-9 in OVCAR5 cells were examined by Western blot and gelatin zymography analysis. The results showed that E2 and selective GPER agonist G-1 increased cell motility and invasiveness, and upregulated the production and proteolytic activity of MMP-9 in OVCAR5 cells. Small interfering RNA (siRNA) targeting GPER and G protein inhibitor pertussin toxin (PTX) inhibited the migration and invasion of OVCAR5 cells, and also reduced the expression and activity of MMP-9. Our data suggested that GPER promoted the migration and invasion of ovarian cancer cells by increasing the expression and activity of MMP-9. GPER might play an important role in the progression of ovarian cancer.

Keywords

GPER MMP-9 Ovarian cancer Migration Invasion 

Notes

Acknowledgments

This study was supported by Natural Science Foundation of Heilongjiang Province of China (Grant No.: D201008) and Scientific Research Foundation for Postdoctoral Researchers of Heilongjiang Province (Grant No.: LRB04-248).

References

  1. 1.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130PubMedCrossRefGoogle Scholar
  2. 2.
    Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351:2519–2529PubMedCrossRefGoogle Scholar
  3. 3.
    Hunn J, Rodriguez GC (2012) Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol 55:3–23PubMedCrossRefGoogle Scholar
  4. 4.
    Bardin A, Hoffmann P, Boulle N, Katsaros D, Vignon F, Pujol P, Lazennec G (2004) Involvement of estrogen receptor beta in ovarian carcinogenesis. Cancer Res 64:5861–5869PubMedCrossRefGoogle Scholar
  5. 5.
    Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W, Dubeshter B (1996) Tamoxifen in platinum-refractory ovarian cancer: a gynecologic oncology group ancillary report. Gynecol Oncol 62:4–6PubMedCrossRefGoogle Scholar
  6. 6.
    Havrilesky LJ, McMahon CP, Lobenhofer EK, Whitaker R, Marks JR, Berchuck A (2001) Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones. J Soc Gynecol Investig 8:104–113PubMedCrossRefGoogle Scholar
  7. 7.
    Wang D, Hu L, Zhang G, Zhang L, Chen C (2010) G protein-coupled receptor 30 in tumor development. Endocrine 38:29–37PubMedCrossRefGoogle Scholar
  8. 8.
    Prossnitz ER, Barton M (2011) The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol 7:715–726PubMedCrossRefGoogle Scholar
  9. 9.
    Ruan SQ, Wang ZH, Wang SW, Fu ZX, Xu KL, Li DB, Zhang SZ (2012) Heregulin-β1-induced GPR30 upregulation promotes the migration and invasion potential of SkBr3 breast cancer cells via ErbB2/ErbB3-MAPK/ERK pathway. Biochem Biophys Res Commun 420:385–390PubMedCrossRefGoogle Scholar
  10. 10.
    Du GQ, Zhou L, Chen XY, Wan XP, He YY (2012) The G protein-coupled receptor GPR30 mediates the proliferative and invasive effects induced by hydroxytamoxifen in endometrial cancer cells. Biochem Biophys Res Commun 420:343–349PubMedCrossRefGoogle Scholar
  11. 11.
    Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, Verschraegen CF, Hathaway HJ, Joste NE, Prossnitz ER (2009) GPR30 predicts poor survival for ovarian cancer. Gynecol Oncol 114:465–471PubMedCrossRefGoogle Scholar
  12. 12.
    Kolkova Z, Casslén V, Henic E, Ahmadi S, Ehinger A, Jirström K, Casslén B (2012) The G protein-coupled estrogen receptor 1 (GPER/GPR30) does not predict survival in patients with ovarian cancer. J Ovarian Res 5:9PubMedCrossRefGoogle Scholar
  13. 13.
    Liu HD, Yan Y, Cao XF, Tan PZ, Wen HX, Lv CM, Li XM, Liu GY (2010) The expression of a novel estrogen receptor, GPR30, in epithelial ovarian carcinoma and its correlation with MMP-9. Sheng Li Xue Bao 62:524–528PubMedGoogle Scholar
  14. 14.
    Sporn MB (1996) The war on cancer. Lancet 347:1377–1381PubMedCrossRefGoogle Scholar
  15. 15.
    Auersperg N, Ota T, Mitchell GW (2002) Early events in ovarian epithelial carcinogenesis: progress and problems in experimental approaches. Int J Gynecol Cancer 12:691–703PubMedCrossRefGoogle Scholar
  16. 16.
    Song J, Fadiel A, Edusa V, Chen Z, So J, Sakamoto H, Fishman DA, Naftolin F (2005) Estradiol-induced ezrin overexpression in ovarian cancer: a new signaling domain for estrogen. Cancer Lett 220:57–65PubMedCrossRefGoogle Scholar
  17. 17.
    Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D (2009) Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J 28:523–532PubMedCrossRefGoogle Scholar
  18. 18.
    He YY, Du GQ, Cai B, Yan Q, Zhou L, Chen XY, Lu W, Yang YX, Wan XP (2012) Estrogenic transmembrane receptor of GPR30 mediates invasion and carcinogenesis by endometrial cancer cell line RL95-2. J Cancer Res Clin Oncol 138:775–783PubMedCrossRefGoogle Scholar
  19. 19.
    Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM, Sabo E (2006) Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res 12:6359–6366PubMedCrossRefGoogle Scholar
  20. 20.
    Smith HO, Leslie KK, Singh M, Qualls CR, Revankar CM, Joste NE, Prossnitz ER (2007) GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol 196:386.e1–386.e11CrossRefGoogle Scholar
  21. 21.
    Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI, Prossnitz ER, Musti AM, Andò S, Maggiolini M (2007) G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res 67:1859–1866PubMedCrossRefGoogle Scholar
  22. 22.
    Lau MT, So WK, Leung PC (2012) Integrin β1 mediates epithelial growth factor-induced invasion in human ovarian cancer cells. Cancer Lett 320:198–204PubMedCrossRefGoogle Scholar
  23. 23.
    Henic E, Noskova V, Høyer-Hansen G, Hansson S, Casslén B (2009) Estradiol attenuates EGF-induced rapid uPAR mobilization and cell migration via the G-protein-coupled receptor 30 in ovarian cancer cells. Int J Gynecol Cancer 19:214–222PubMedCrossRefGoogle Scholar
  24. 24.
    Peng TL, Chen J, Mao W, Song X, Chen MH (2009) Aryl hydrocarbon receptor pathway activation enhances gastric cancer cell invasiveness likely through a c-Jun-dependent induction of matrix metalloproteinase-9. BMC Cell Biol 10:27PubMedCrossRefGoogle Scholar
  25. 25.
    Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R, Fidler IJ (2002) Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 94:1134–1142PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Laboratory of Reproductive Endocrinology, Department of PhysiologyHarbin Medical UniversityNangang District, HarbinChina
  2. 2.Genomics Research CenterHarbin Medical UniversityHarbinChina
  3. 3.Department of Obstetrics and GynecologyThe First Affiliated Hospital of Harbin Medical UniversityNangang District, HarbinChina

Personalised recommendations